Six severely ill patients received the CCR5 inhibi
Post# of 148331
(Total Views: 820)
Posted On: 04/25/2020 5:06:27 PM
Quote:
Six severely ill patients received the CCR5 inhibitor leronlimab (PRO 140, CytoDyn) on a compassionate-use basis,
Why NEJM mentioned compassionate-use in its paper? Does Lero get approval for compassionate use?
https://www.nejm.org/doi/full/10.1056/NEJMc20...oronavirus
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼